Welcome to the AD/PD™ 2021 Interactive Program
The congress will officially run on Central European Time (CET) - Barcelona Time
To convert the congress times to your local time Click Here
Icons Legend: ![]()
- Live Session | 
- On Demand Session | 
- On Demand with Live Q&A
The viewing of sessions, cannot be accessed from this conference calendar. All sessions are accessible via the Main Lobby.
Session Description
Join us for a presentation and discussion from two prospective studies evaluating gamma sensory stimulation as a novel therapeutic intervention for Alzheimer’s disease. The panel will be moderated by Dr. Li-Huei Tsai of MIT, who’s pioneering systems neuroscience research established the basis of this therapeutic approach. Joining Dr. Tsai are Dr. James Lah, principal investigator of the Flicker study at Emory University, Dr. Tom Megerian, CMO of Cognito Therapeutics, and Dr. Suzanne Hendrix, CEO of Pentara Corporation, who will present the design and results of the multi-center Overture randomized controlled trial.
Gamma sensory stimulation, a novel AD therapeutic intervention: initial safety, efficacy and biomarker changes from two prospective clinical studies
SUPPORTED BY Cognito Therapeutics
Welcome and introduction
Scientific Background
Design and outcomes of the Flicker study
Study design of the Phase 2 Overture randomized controlled trial
Results of the Phase 2 Overture study
Panel Discussion
Live Q&A